Lilium Otsuka appears in FDA device records as the applicant for a single premarket notification, K260605, covering Lilium one (USM330). The filing sits under product code IYO and regulation 21 CFR 892.1560, within the radiology advisory committee, and FDA recorded a substantially equivalent decision on October 16, 2026. The device identity and intended function are documented in the manufacturer's published materials, which describe a portable ultrasound device that measures urine volume in the bladder. [1][4][6]
The K260605 submission and its scope
FDA's record for K260605 lists Lilium Otsuka Co., Ltd. as applicant and Lilium one (USM330) as the device, with a Traditional submission type, a receipt date of February 24, 2026, and a decision date of October 16, 2026. The decision code SESE corresponds to a substantially equivalent determination, and the record notes a summary statement. The review was assigned to the radiology advisory committee under product code IYO. [1][6]
The regulation cited in the filing record is 21 CFR 892.1560, and the openFDA device classification fields associated with the record describe a class 2 ultrasonic pulsed echo imaging system within radiology. The submission carries a third-party review flag in the FDA data. These fields describe the filing's regulatory placement, not the clinical performance of the device. [1][6]
What Lilium one is documented to do
Otsuka Pharmaceutical Factory's December 12, 2022 release announced Lilium one as a portable ultrasonic diagnostic device for the bladder, described as a medical device that measures urine volume in the bladder using ultrasound and as specialized for single measurement. The same release states a launch date of March 1, 2023. The release also notes that residual urine volume is used as an indicator for diagnosis and treatment, without specifying clinical thresholds. [4][5]
Lilium Otsuka's own site presents Lilium one as a bladder scanner built around one-button operation and single-measurement use at the point of care, and carries a notice that the device was pending 510(k) clearance and not available for sale in the United States at the time of that notice. The site also records the company's exhibition at the AUA Annual Meeting 2026. [3]
Corporate identity and relationship to Otsuka Pharmaceutical Factory
An April 27, 2018 announcement from Otsuka Pharmaceutical Factory states that it signed an agreement to acquire all shares of Lilium Otsuka held by Otsuka Medical Devices, making Lilium Otsuka a wholly owned subsidiary. That document describes Lilium Otsuka's business as research and development, manufacturing and marketing of medical devices and related products. [7]
The 2022 launch release for Lilium one was issued by Otsuka Pharmaceutical Factory, which identifies Lilium Otsuka's location as Sagamihara, Kanagawa, and lists 18 employees as of December 31, 2021. The FDA filing record separately lists a Kanagawa address for the applicant; that filing address is not treated here as a verified headquarters. [1][4][7]
How to read the filing record
The linked collection for this company contains one 510(k) record, K260605, and the decision count for that collection is one substantially equivalent determination. The record sample likewise contains that single entry, so the sample and collection denominators coincide at one. These counts describe the filings retrieved as of November 20, 2026, and are not measures of sales, total portfolio or safety performance. [1]
No recall records are included in the retrieved collection, and no other FDA pathways appear. Absence of additional filings in this collection does not establish that none exist. The Innolitics index entry for K260605 repeats the applicant, product code, decision date and decision code recorded by FDA. [1][6]

